PolyPid Announces Receipt of Qualified Infectious Disease Product (QIDP) Designation from FDA for D-PLEX100 in Post-Cardiac Surgery Sternal Infection
QIDP Designation Allows for FDA Priority Review and Adds Five Years of Market Exclusivity for D-PLEX™. D-PLEX™ Currently Subject of On-going Phase Ib/II Study in Israel. Company Intends to Seek Regulatory Approvals in U.S. and Europe in Coming Year to Conduct Phase III Clinical Trial of D-PLEX™. Petah Tikva, Israel, March 08, 2017 -- PolyPid…
Read more >